Introduction Pyrimidine nucleotides are essential for the parasite's growth and replication.
Parasites have only a de novo pathway for the biosynthesis of pyrimidine nucleotides …

Malaria is a critical human disease with extensive exploration yet unestablished due to
occurrence of frequent drug resistance. This aspect of malaria pharmacology calls for the …

A Plasmodium falciparum dihydroorotate dehydrogenase (Pf DHODH) inhibitor that is potent
(KI= 15 nM) and species-selective (> 5000-fold over the human enzyme) was identified by …

Plasmodium falciparum, the causative agent of the most deadly form of human malaria, is
unable to salvage pyrimidines and must rely on de novo biosynthesis for survival …

The de novo pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase is an emerging
drug target for the treatment of malaria. In this context a key property of Plasmodium …

Pyrimidine biosynthesis presents an attractive drug target in malaria parasites due to the
absence of a pyrimidine salvage pathway. A set of compounds designed to inhibit the …

Inhibition of dihydroorotate dehydrogenase (DHODH) for P. falciparum potentially
represents a new treatment option for malaria, since DHODH catalyzes the rate-limiting step …

Plasmodium falciparum is the causative agent of the most serious and fatal malarial
infections, and it has developed resistance to commonly employed chemotherapeutics. The …

Taking the emergence of drug resistance and lack of effective antimalarial vaccines into
consideration, it is of significant importance to develop novel antimalarial agents for the …

Malaria remains one of the most lethal infectious diseases worldwide, and the most severe
form is caused by Plasmodium falciparum. In recent decades, the major challenge to …